Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.46 |
| ▸ | CDK4 | P11802 | 3/20 | 0.41 |
| ▸ | CCND1 | P24385 | 3/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11168356 | 0.95 | SLC6A2 (0.50) | SLC6A2SLC6A4CDK4CCND1BRD4 | |
| SCHEMBL20037238 | 0.90 | SLC6A2 (0.57) | SLC6A2SLC6A4CDK4CCND1BRD4 | |
| SCHEMBL24729036 | 0.82 | SLC6A2 (0.49) | SLC6A2SLC6A4CDK4CCND1 | |
| SCHEMBL599150 | 0.82 | SLC6A2 (0.49) | SLC6A2SLC6A4CDK4CCND1 | |
| SCHEMBL10963090 | 0.82 | SLC6A2 (0.50) | SLC6A2SLC6A4CDK4CCND1 | |
| SCHEMBL11393736 | 0.82 | SLC6A2 (0.50) | SLC6A2SLC6A4CDK4CCND1 | |
| SCHEMBL10774534 | 0.80 | SLC6A2 (0.51) | SLC6A2SLC6A4CDK4CCND1 | |
| SCHEMBL22810523 | 0.79 | SLC6A2 (0.50) | SLC6A2SLC6A4CDK4CCND1 | |
| SCHEMBL23940244 | 0.78 | SLC6A2 (0.52) | SLC6A2SLC6A4CDK4CCND1 | |
| SCHEMBL23940127 | 0.78 | SLC6A2 (0.49) | SLC6A2SLC6A4CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11077433-B2 | Production of fatty olefin derivatives via olefin metathesis | PROVIVI, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200261898-A1 | PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS | PROVIVI, INC. (US) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261898-A1 | PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS | SREBF1, F2, SREBF2 | SLC6A2 4202/4885SLC6A4 4284/4885CDK4 2226/4885 |
| US-11077433-B2 | Production of fatty olefin derivatives via olefin metathesis | SREBF1, F2, SREBF2 | SLC6A2 4202/4885SLC6A4 4284/4885CDK4 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.